Document › Details

MeiraGTx Holdings plc. (8/7/19). "Press Release: MeiraGTx Reports Second Quarter 2019 Financial Results and Provides Corporate Update". London & New York, NY.

Organisations Organisation MeiraGTx Holdings Plc (NASDAQ: MGTX)
  Group MeiraGTx (Group)
  Organisation 2 Janssen Pharmaceuticals Inc.
  Group Johnson & Johnson (JnJ) (Group)
Products Product AAV-CNGA3 gene therapy (MeiraGTx)
  Product 2 AAV-hAQP1 gene therapy (MeiraGTx)
Index term Index term JnJ–MeiraGTx: gene therapy, 201901– collab r+d + license ww excl $100m upfront + milestones + funding + 20% royalties for inherited retinal diseases
Persons Person Forbes, Alexandria (MeiraGTx 201810 CEO)
  Person 2 Pascale, Christiana (W2O Group 201901 at W2O pure)
     


   
Record changed: 2019-08-13

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 650x112px

More documents for MeiraGTx (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

[iito] Business Intelligence – The Elephants Are Coming 560x113px




» top